SMAD2 and neoplasm: By identifying a TGF-β1/TAK1/NF-κB/SMAD2 signalling pathway triggered in NB cells by their interaction with TAM and MSC/CAF, our data brings a new insight into the contribution of TGF-β1 to tumour progression and therapeutic resistance in this cancer.